These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32770582)

  • 1. Elucidating the microscopic and computational techniques to study the structure and pathology of SARS-CoVs.
    Kaniyala Melanthota S; Banik S; Chakraborty I; Pallen S; Gopal D; Chakrabarti S; Mazumder N
    Microsc Res Tech; 2020 Dec; 83(12):1623-1638. PubMed ID: 32770582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Architecture of the SARS coronavirus prefusion spike.
    Beniac DR; Andonov A; Grudeski E; Booth TF
    Nat Struct Mol Biol; 2006 Aug; 13(8):751-2. PubMed ID: 16845391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca
    Straus MR; Tang T; Lai AL; Flegel A; Bidon M; Freed JH; Daniel S; Whittaker GR
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
    Ge XY; Li JL; Yang XL; Chmura AA; Zhu G; Epstein JH; Mazet JK; Hu B; Zhang W; Peng C; Zhang YJ; Luo CM; Tan B; Wang N; Zhu Y; Crameri G; Zhang SY; Wang LF; Daszak P; Shi ZL
    Nature; 2013 Nov; 503(7477):535-8. PubMed ID: 24172901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.
    Pfefferle S; Schöpf J; Kögl M; Friedel CC; Müller MA; Carbajo-Lozoya J; Stellberger T; von Dall'Armi E; Herzog P; Kallies S; Niemeyer D; Ditt V; Kuri T; Züst R; Pumpor K; Hilgenfeld R; Schwarz F; Zimmer R; Steffen I; Weber F; Thiel V; Herrler G; Thiel HJ; Schwegmann-Wessels C; Pöhlmann S; Haas J; Drosten C; von Brunn A
    PLoS Pathog; 2011 Oct; 7(10):e1002331. PubMed ID: 22046132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topographic changes in SARS coronavirus-infected cells at late stages of infection.
    Ng ML; Lee JW; Leong ML; Ling AE; Tan HC; Ooi EE
    Emerg Infect Dis; 2004 Nov; 10(11):1907-14. PubMed ID: 15550199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction.
    Witkowska D
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronavirus envelope protein: current knowledge.
    Schoeman D; Fielding BC
    Virol J; 2019 May; 16(1):69. PubMed ID: 31133031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.
    Musarrat F; Chouljenko V; Dahal A; Nabi R; Chouljenko T; Jois SD; Kousoulas KG
    J Med Virol; 2020 Oct; 92(10):2087-2095. PubMed ID: 32374457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
    Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M
    J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of Vero E6 cell clones persistently infected with severe acute respiratory syndrome coronavirus.
    Yamate M; Yamashita M; Goto T; Tsuji S; Li YG; Warachit J; Yunoki M; Ikuta K
    Microbes Infect; 2005 Dec; 7(15):1530-40. PubMed ID: 16269264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus.
    Nagata N; Iwata N; Hasegawa H; Fukushi S; Yokoyama M; Harashima A; Sato Y; Saijo M; Morikawa S; Sata T
    J Virol; 2007 Feb; 81(4):1848-57. PubMed ID: 17151094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody.
    Ng OW; Keng CT; Leung CS; Peiris JS; Poon LL; Tan YJ
    PLoS One; 2014; 9(7):e102415. PubMed ID: 25019613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Virus-Receptor Interplay Influence Human Coronaviruses Infection Outcome?
    Bratosiewicz-Wąsik J; Wąsik TJ
    Med Sci Monit; 2020 Dec; 26():e928572. PubMed ID: 33311429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor.
    Babcock GJ; Esshaki DJ; Thomas WD; Ambrosino DM
    J Virol; 2004 May; 78(9):4552-60. PubMed ID: 15078936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface ultrastructure of SARS coronavirus revealed by atomic force microscopy.
    Lin S; Lee CK; Lee SY; Kao CL; Lin CW; Wang AB; Hsu SM; Huang LS
    Cell Microbiol; 2005 Dec; 7(12):1763-70. PubMed ID: 16309462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction.
    Lau SY; Wang P; Mok BW; Zhang AJ; Chu H; Lee AC; Deng S; Chen P; Chan KH; Song W; Chen Z; To KK; Chan JF; Yuen KY; Chen H
    Emerg Microbes Infect; 2020 Dec; 9(1):837-842. PubMed ID: 32301390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
    Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
    Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.